Vascular endothelial growth factor expression and inhibition in uveal melanoma cell lines

ecancermedicalscience

Volumn 7, Issue 1, 2013, Pages

  Logan, Patrick ^a   Burnier, Julia ^a   Burnier Jr , Miguel N ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Bevacizumab; Invasion; Migration; Proliferation; Uveal melanoma; VEGF A

Indexed keywords

BEVACIZUMAB; GAMMA INTERFERON; GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; SULFORHODAMINE B; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; UPREGULATION; UVEA MELANOMA; WESTERN BLOTTING;

EID: 84883345017     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2013.336     Document Type: Article

References (69)

1. Katz NR, et al (1995) Ultrasound biomicroscopy in the management of malignant melanoma of the iris Arch Ophthalmol 113 1462-3 DOI: 10.1001/archopht.1995.01100110122037 PMID: 7487612
2. Singh AD and Topham A (2003) Incidence of uveal melanoma in the United States: 1973-1997 Ophthalmology 110 956-61 DOI: 10.1016/S0161-6420(03)00078-2 PMID: 12750097
3. Hawkins BS (2004) The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24 Am J Ophthalmol 138 936-51 DOI: 10.1016/j.ajo.2004.07.006
4. (1998) The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma II: initial mortality findings. COMS report no. 10 Am J Ophthalmol 125 779-796 PMID: 9645716
5. Rajpal S, Moore R and Karakousis CP (1983) Survival in metastatic ocular melanoma Cancer 52 334-6 DOI: 10.1002/1097-0142- (19830715)52:2<334::AID- CNCR2820520225>3.0.CO;2-E PMID: 6190546
6. Char DH (1978) Metastatic choroidal melanoma Am J Ophthalmol 86 76-80 PMID: 677236
7. Einhorn LH, Burgess MA and Gottlieb JA (1974) Metastatic patterns of choroidal melanoma Cancer 34 1001-4 DOI: 10.1002/1097- 0142(197410)34:4<1001: :AID-CNCR2820340406>3.0.CO;2-Z PMID: 4424282
8. Mavligit GM, et al (1988) Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge JAMA 260 974-6 DOI: 10.1001/jama.1988.03410070102037 PMID: 3398202
9. Singh AD and Topham A (2003) Survival rates with uveal melanoma in the United States: 1973-1997 Ophthalmology 110 962-5 DOI: 10.1016/S0161-6420(03) 00077-0 PMID: 12750098
10. Spagnolo F, Caltabiano G and Queirolo P (2012) Uveal melanoma Cancer Treat Rev 38 549-53 DOI: 10.1016/j.ctrv.2012.01.002 PMID: 22270078
11. Frenkel S, et al (2009) Long-term survival of uveal melanoma patients after surgery for liver metastases Br J Ophthalmol 93 1042-6 DOI: 10.1136/bjo.2008.153684 PMID: 19429579
12. Mariani P, et al (2009) Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie Eur J Surg Oncol: J Eur Soc Surg Oncol Br Assoc Surg Oncol 35 1192-7 DOI: 10.1016/j.ejso.2009.02.016
13. Kodjikian L, et al (2005) Prognostic factors of liver metastases from uveal melanoma Graefe's Arch Clin Exp Ophthalmol (Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie) 243 985-93 DOI: 10.1007/s00417-005-1188-8 PMID: 15891893
14. Folkman J, Merler E, Abernathy C and Williams G (1971) Isolation of a tumor factor responsible for angiogenesis J Exp Med 133 275-88 DOI: 10.1084/jem.133.2.275 PMID: 4332371
15. Ferrara N and Davis-Smyth T (1977) The biology of vascular endothelial growth factor Endocr Rev 18 4-25 DOI: 10.1210/er.18.1.4
16. Shibuya M and Claesson-Welsh L (2006) Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis Exp Cell Res 312 549-60 DOI: 10.1016/j.yexcr.2005.11.012
17. Hanahan D and Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 353-64 DOI: 10.1016/S0092- 8674(00)80108-7 PMID: 8756718
18. Takahashi S (2011) Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy Biol Pharm Bull 34 1785-8 DOI: 10.1248/bpb.34.1785 PMID: 22130231
19. Folkman J (1971) Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182-6 DOI: 10.1056/NEJM197111182852108 PMID: 4938153
20. Lai GG and Penson RT (2011) Bevacizumab and ovarian cancer Drugs Today (Barc) 47 669-81 DOI: 10.1358/dot.2011.47.9.1673557
21. Boyd SR, et al Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window Br J Ophthalmol 86 448-52 PMID: 11914216 PMCID: 1771104
22. Missotten GS, et al (2006) Vascular endothelial growth factor a in eyes with uveal melanoma Arch Ophthalmol 24 1428-34 DOI: 10.1001/archopht.124.10.1428
23. Ijland SA, Jager MJ, Heijdra BM, Westphal JR and Peek R (1999) Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines Melanoma Res 9 445-50 DOI: 10.1097/00008390-199910000-00003 PMID: 10596910
24. el Filali M, et al (2010) Regulation of VEGF-A in uveal melanoma Invest Ophthalmol Visual Sci 51 2329-37 DOI: 10.1167/iovs.09- 4739
25. Crosby MB, Yang H, Gao W, Zhang L and Grossniklaus HE (2011) Serum vascular endothelial growth factor (VEGF) levels correlate with number and location of micrometastases in a murine model of uveal melanoma Br J Ophthalmol 95 112-7 DOI: 10.1136/bjo.2010.182402
26. Boyd SR, et al (2002) Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth Br J Ophthalmol 86 440-7 DOI: 10.1136/bjo.86.4.440 PMID: 11914215
27. Sheidow TG, Hooper PL, Crukley C, Young J and Heathcote JG (2000) Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis Br J Ophthalmol 84 750-6 DOI: 10.1136/bjo.84.7.750 PMID: 10873988
28. Presta LG, et al (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 4593-9 PMID: 9377574
29. Yang H, Jager MJ and Grossniklaus HE (2010) Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma Invest Ophthalmol Visual Sci 51 2835-42 DOI: 10.1167/iovs.09-4755
30. Clinical Trials (2008). http://clinicaltrials.gov/ct2/show/NCT00596362
31. Piperno-Neumann SSV, Bidard F-C, Mariani P, Plancher C, Asselain B, Vago-Ady N, Desjardins L (2012) BEVATEM: phase II single-center study of bevacizumab in combination with temozolomide in patients (pts) with first-line metastatic uveal melanoma (MUM): first-step results. American Society of Clinical Oncology J Clin Oncol 30 http://meetinglibrary.asco.org/content/95035- 114
32. De Waard-Siebinga I, et al (1995) Establishment and characterization of an uveal-melanoma cell line Inter J Cancer (Journal international du cancer) 62 155-61 DOI: 10.1002/ijc.2910620208
33. Marshall JC, Caissie AL, Callejo SA, Antecka, E and Burnier Jr MN (2004) Cell proliferation profile of five human uveal melanoma cell lines of different metastatic potential Pathobiol: J Immunopathol, Mol Cell Biol 71 241-5 DOI: 10.1159/000080057
34. Diebold Y, Blanco G, Saornil MA, Fernandez N and Lazaro MC (1997) Morphologic and immunocytochemical characterization of four human uveal cell lines (melanoma- and melanocytes-derived) Curr Eye Res 16 487-95 DOI: 10.1076/ceyr.16.5.487.7047 PMID: 9154388
35. Strober W (2001) Trypan blue exclusion test of cell viability Curr Protocols Immunol/edited by John E. Coligan ... [et al.] Appendix 3, Appendix 3B, DOI: 10.1002/0471142735.ima03bs21
36. Abramoff MD, Magalhaes PJ and Ram SJ (2004) Image processing with ImageJ Biophotonics Inter 11 36-42
37. Kaczmarek E, Górna A and Majewski P (2004) Techniques of image analysis for quantitative immunohistochemistry Rocz Akad Med Bialymst 49(Suppl 1) 155-8 PMID: 15638406
38. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR Nucleic Acids Res 29 e45 DOI: 10.1093/nar/29.9.e45 PMID: 11328886 PMCID: 55695
39. Skehan P, et al (1990) New colorimetric cytotoxicity assay for anticancer-drug screening J Natl Cancer Inst 82 1107-12 DOI: 10.1093/jnci/82.13.1107 PMID: 2359136
40. Cools-Lartigue J, Marshall JC, Caissie AL, Saraiva VS and Burnier MN, Jr (2005) Secretion of hepatocyte growth factor and vascular endothelial growth factor during uveal melanoma-monocyte in vitro interactions Melanoma Res 15 141-5 DOI: 10.1097/00008390-200506000-00001 PMID: 15917694
41. Barak V, Pe'er J, Kalickman I and Frenkel S (2011) VEGF as a biomarker for metastatic uveal melanoma in humans Curr Eye Res 36: 386-390 DOI: 10.3109/02713683.2010.534573 PMID: 21284506
42. Avery RL, et al (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy Ophthalmology 113 1695 e1691-1615 DOI: 10.1016/j.ophtha.2006.05.064 PMID: 17011951
43. Biswas P, et al (2011) Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration Ind J Ophthalmol 59 191-6 DOI: 10.4103/0301-4738.81023
44. Steinbrook R (2006) The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration New Engl J Med 355 1409-12 DOI: 10.1056/NEJMp068185 PMID: 17021315
45. Wu WC, et al (2011) Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan Ophthalmology 118 176-83 DOI: 10.1016/j.ophtha.2010.04.018
46. Lefevre G, et al Activation of the FGF2/FGFR1 autocrine loop for cell proliferation and survival in uveal melanoma cells Invest Ophthalmol Visual Sci 50 1047-57 DOI: 10.1167/iovs.08-2378
47. de Jong JS, van Diest PJ, van der Valk P and Baak JP (1998) Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis J Pathol 184 53-7 DOI: 10.1002/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO;2-7 PMID: 9582527
48. Boocock CA, et al (1995) Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma J Natl Cancer Inst 87 506-16 DOI: 10.1093/jnci/87.7.506 PMID: 7707437
49. Jackson MW, et al (2002) A potential autocrine role for vascular endothelial growth factor in prostate cancer Cancer Res 62 854-9 PMID: 11830543
50. Fan F, et al (2011) Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration Br J Cancer 104 1270-7 DOI: 10.1038/bjc.2011.81 PMID: 21407219 PMCID: 3078594
51. Forooghian F, Kertes PJ, Eng KT, Agron E and Chew EY (2010) Alterations in the intraocular cytokine milieu after intravitreal bevacizumab Invest Ophthalmol Visual Sci 51 2388-92 DOI: 10.1167/iovs.09-4065
52. Molhoek KR, et al (2008) Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2 Cancer Res 68 4392-7 DOI: 10.1158/0008-5472.CAN- 07-5844 PMID: 18519701
53. Emlet DR, et al (2007) Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines Mol Cancer Therapeutics 6 2664-74 DOI: 10.1158/1535-7163.MCT-07-0079
54. Holmes K, Roberts OL, Thomas AM and Cross MJ (2007) Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition Cell Signal 19 2003-2012 DOI: 10.1016/j.cellsig.2007.05. 013 PMID: 17658244
55. Asnaghi L, et al (2012) Notch signaling promotes growth and invasion in uveal melanoma Clin Cancer Res: Official J Am Assoc Cancer Res 18 654-65 DOI: 10.1158/1078-0432.CCR-11-1406
56. Jubb AM, Oates AJ, Holden S and Koeppen H (2006) Predicting benefit from anti-angiogenic agents in malignancy Nat Rev Cancer 6: 626-35 DOI: 10.1038/nrc1946 PMID: 16837971
57. Jubb AM, et al (2012) Expression of vascular Notch ligands Delta-like 4 and Jagged-1 in glioblastoma Histopathology 60 740-7 DOI: 10.1111/j.1365-2559. 2011.04138.x PMID: 22296176
58. DarringtonE, Zhong M, Vo BH and Khan SA (2012) Vascular endothelial growth factor A, secreted in response to transforming growth factor-beta1 under hypoxic conditions, induces autocrine effects on migration of prostate cancer cells Cell and Mol Immunol DOI: 10.1038/aja.2011.197
59. Valleala H, et al (2003) Regulation of MMP-9 (gelatinase B) in activated human monocyte/macrophages by two different types of bisphosphonates Life Sci 73 2413-20 DOI: 10.1016/S0024-3205(03)00657-X PMID: 12954450
60. El-Shabrawi Y, Ardjomand N and Radner H (2001) MMP-9 is predominantly expressed in epithelioid and not spindle cell uveal melanoma J Pathol 194 201-6 DOI: 10.1002/1096-9896(200106)194:2<201::AID-PATH840>3.0.CO;2-O PMID: 11400149
61. Maurer M and von Stebut E (2004) Macrophage inflammatory protein-1 Inter J Biochem Cell Biol 36 1882-6 DOI: 10.1016/j. biocel.2003.10.019
62. Harlin H et al (2009) Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment Cancer Res 69 3077-85 DOI: 10.1158/0008-5472.CAN-08-2281 PMID: 19293190
63. Ly LV, et al (2010) Inflammatory cytokines in eyes with uveal melanoma and relation with macrophage infiltration Invest Ophthalmol Visual Sci 51 5445-51 DOI: 10.1167/iovs.10-5526
64. Yang X, et al (2006) Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression Inter J Cancer (Journal international du cancer) 118 1869-76 DOI: 10.1002/ijc.21596
65. Park JE, Keller GA and Ferrara N (1993) The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF Mol Biol Cell 4 1317-26 PMID: 8167412
66. Le Y, Zhou Y, Iribarren P and Wang J (2004) Chemokines and chemokine receptors: their manifold roles in homeostasis and disease Cell Mol Immunol 1 95-104 PMID: 16212895
67. Makitie T, Summanen P, Tarkkanen A and Kivela T (2001) Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma Invest Ophthalmology Visual Sci 42 1414-21
68. Lu P, Li L, Wu Y, Mukaida N and Zhang X (2008) Essential contribution of CCL3 to alkali-induced corneal neovascularization by regulating vascular endothelial growth factor production by macrophages Mol Vision 14 1614-22 PMID: 18776949
69. Jeong JH, Chun YS, Kim ES and Kim JC (2011) Compensatory growth factor and cytokine response in tears after subconjunctival bevacizumab injection Cornea 30 1071-7 DOI: 10.1097/ICO.0b013e31820cd3f4 PMID: 21775887